Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting

Basit Öğe Kaydı
dc.authoridTERZİ, Murat/0000-0002-3586-9115
dc.authoridköseoğlu, mesrure/0000-0003-0469-0064
dc.authoridUNAL, Aysun/0000-0002-7702-8437
dc.authorwosidEFENDI, HÜSNÜ/JUU-8107-2023
dc.authorwosidBOZ, Cavit/V-5127-2017
dc.authorwosidTERZİ, Murat/AAA-1284-2021
dc.authorwosidköseoğlu, mesrure/KAM-4152-2024
dc.authorwosidAltunan, Bengu/ACD-3118-2022
dc.contributor.authorAltunan, Bengu
dc.contributor.authorUnal, Aysun
dc.contributor.authorEfendi, Husnu
dc.contributor.authorKoseoglu, Mesrure
dc.contributor.authorTerzi, Murat
dc.contributor.authorKotan, Dilcan
dc.contributor.authorTamam, Yusuf
dc.date.accessioned2024-06-12T11:02:05Z
dc.date.available2024-06-12T11:02:05Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with MS (pwMS) should be a priority. We aimed to evaluate the efficacy, safety and treatment satisfaction of one of the FO-Fingolimod (FTY) used in Turkey with the approval of Turkish Ministry of Health.Methods: PwMS under FTY were recruited from 13 centers and real-world data and answers of satisfaction and adherence statements of pwMS on FTY treatment were analyzed.Results: Data of 239 pwMS were obtained. The duration of FTY treatment was 2.5 & PLUSMN; 0.8 (1-4) years in pwMS who were included in the study and whose treatment continued for at least one year. Significant decreases in annual relapse rate (p < 0.001), Expanded Disability Status Scale (p < 0.001) and neuroimaging findings (p < 0.001) were observed. While 64% of the patients were satisfied and 71.5% were found to adherent with this FO-FTY.Conclusion: This multicenter retrospective study found that the efficacy, safety and treatment adherence of a prescribed FO-FTY were consistent with the results of real-world studies. Studies including real-world data may provide guidance to address issues related to FO-FTY use.en_US
dc.identifier.doi10.1016/j.msard.2023.104880
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid37459716en_US
dc.identifier.scopus2-s2.0-85165251046en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.msard.2023.104880
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21143
dc.identifier.volume77en_US
dc.identifier.wosWOS:001039758400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofMultiple Sclerosis And Related Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFollow-On Drugen_US
dc.subjectGeneric Fingolimoden_US
dc.subjectReal-World Dataen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectSatisfactionen_US
dc.subjectAdherenceen_US
dc.subjectOral Fingolimoden_US
dc.subjectMulticenteren_US
dc.subjectEfficacyen_US
dc.subjectQualityen_US
dc.subjectSafetyen_US
dc.titleUse of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical settingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu